The9's Investee Nanyang Biologics Merges to Revolutionize AI-Driven Drug Discovery

Nanyang Biologics Pioneers Drug Discovery through AI Integration

Nanyang Biologics Pte. Ltd. (NYB), an investee company of The9 Limited, is on the verge of a significant transformation as it finalizes a business combination agreement with RF Acquisition Corp II. This merger is set to elevate NYB into a publicly listed entity valued at approximately $1.5 billion. With formal approval from both companies' boards, the transaction is expected to conclude in the first or second quarter of 2026, pending shareholder approval and customary closing conditions. This strategic move positions NYB to leverage its advanced artificial intelligence platform in the drug discovery field, aiming to streamline the identification of effective drug molecules and natural ingredients essential for pharmaceuticals and traditional medicine.

The emphasis on AI-driven drug discovery technology is a critical development for NYB, as it seeks to enhance its capabilities in an increasingly competitive biopharmaceutical landscape. By harnessing the power of artificial intelligence, NYB plans to improve the efficiency of its drug development processes, potentially accelerating the time to market for innovative therapeutics. This initiative aligns with the growing trend within the industry towards integrating technology into healthcare solutions, especially in the realm of biopharmaceuticals that require precise molecular screening. NYB's strategy not only enhances its operational efficiency but also aims to ensure that emerging treatments meet rigorous safety and efficacy standards.

Recognition of NYB's innovative approach is underscored by its recent accolade of winning 1st Prize at the SuperAI Genesis Startup Competition 2025, where it stood out among over 700 regional competitors. Further solidifying its position in the industry, NYB has entered into a Memorandum of Understanding with prominent tech companies, including Nvidia, Hewlett Packard Enterprise, and Equinix, to construct the world's largest natural compound library. This collaboration aims to establish scalable AI platforms for drug discovery and develop secure infrastructure for healthcare innovations, emphasizing the importance of protecting sensitive scientific data crucial for advancing drug development.

In addition to its ongoing projects, NYB boasts a robust portfolio of patents that support its drug-candidate pipeline and proprietary nutraceuticals. As it progresses toward its merger, NYB is set to designate a majority of the board for the combined entity, ensuring that existing shareholders, including The9, maintain a majority stake in the new company. This strategic positioning not only reflects NYB's commitment to innovation but also highlights its potential to lead in the rapidly evolving landscape of drug discovery and biopharmaceutical development.

As NYB prepares for its public listing, its focus on integrating AI in healthcare represents a significant shift in how biopharmaceutical companies approach drug discovery and development, potentially paving the way for groundbreaking advancements in the industry.